Review of minimal access versus transcatheter aortic valve replacement for patients with severe aortic stenosis

Carson T. Hoffmann, Jacob A. Heiner, Tom C. Nguyen

Department of Cardiothoracic and Vascular Surgery, McGovern Medical School, University of Texas at Houston, Memorial Hermann Hospital—Heart and Vascular Institute, Houston, Texas, USA

Correspondence to: Tom C. Nguyen, MD. Department of Cardiothoracic and Vascular Surgery, University of Texas, Memorial Hermann, 6400 Fannin Street, Suite 2850, Houston, Texas 77030, USA. Email: tom.c.nguyen@gmail.com.

Transcatheter aortic valve replacement (TAVR) and minimally invasive aortic valve replacement (miniAVR) have become alternatives to surgical aortic valve replacement via median sternotomy (SAVR) to treat severe aortic stenosis (AS). Despite increased interest and utilization, few studies have directly compared TAVR and miniAVR. A review of the current literature shows TAVR to be an indispensable tool for inoperable, high-risk, and perhaps intermediate-risk patients with severe AS. However, it is associated with a number of deleterious perioperative outcomes, such as valvular regurgitation and vascular complications. MiniAVR is associated with decreased intensive care unit (ICU) and hospital length of stay, a lower incidence of blood transfusions, decreased ventilation time, and improved cosmetic results. MiniAVR maintains potential advantages over SAVR, including the implantation of a durable prosthesis and low rates of perioperative myocardial infarction and paravalvular leak. It is associated with longer aortic cross clamp and cardiopulmonary bypass (CPB) times; however, the use of sutureless valve implants can circumvent this. Studies comparing TAVR and miniAVR demonstrate decreased postoperative mortality, valvular regurgitation, and incidence of stroke in the miniAVR cohorts. Few studies currently exist comparing TAVR and miniAVR, as it is hard to compare the typically low-risk miniAVR versus high-risk TAVR patient populations. It is clear that both strategies will be cornerstones in the modern AVR era, but the situations in which to apply each strategy have not yet been clearly delineated. This highlights the need for surgeons to adopt these minimally invasive techniques. We believe there is a compelling role for miniAVR in low- and intermediate-risk patients, but due to the paucity of data, neither TAVR nor miniAVR should be discounted before a randomized, risk-stratified trial is performed. More studies are needed to compare TAVR and miniAVR in low- and intermediate-risk patients.

Keywords: Aortic stenosis (AS); aortic valve replacement; minimally invasive; transcatheter

doi: 10.21037/acs.2017.09.02

View this article at: http://dx.doi.org/10.21037/acs.2017.09.02

Introduction

Aortic valve replacement (AVR) is the second most common cardiac procedure performed, with aortic stenosis (AS) being the most common valve disease as a result of an aging population (1). A prospective, population-based study found the incidence of AS to be 0.2% in the 50–59 years cohort, 1.3% in the 60–69 years cohort, 3.9% in the 70–79 years cohort, and 9.8% in the 80–89 years cohort (2). A survival rate of 50% at 2 years and 20% at 5 years after symptom onset has prompted the development of multiple therapeutic strategies (3).

Traditionally, surgical aortic valve replacement via median sternotomy (SAVR) has been the gold standard to treat severe AS, as this approach has been highly successful in providing freedom from structural valve failure rates of 70–90% at 10 years and 50–80% at 15 years (4). However, in this era of advancements in minimally invasive
operations, patients increasingly want the least invasive approach to correct complex problems, assuming that it is safe, as good as the status quo, and potentially cost effective. In recent years, transcatheter aortic valve replacement (TAVR) has emerged as a promising option for high- and potentially intermediate-risk patients, and there are several studies comparing TAVR versus SAVR. The drive towards minimally invasive strategies has also increased the demand and adoption of minimally invasive aortic valve replacement (miniAVR). Nguyen et al. demonstrated an increased growth for both of these techniques between 2011 and 2014 (5). Transfemoral TAVR and miniAVR displayed a 595% and 57% increase from 2011 to 2014, respectively (5). Johnston and Roselli reported an increase in miniAVR from 12.4% to 29.6% of the total aortic valve procedures at the Cleveland Clinic, from 1996 to 2013 (6).

Despite the increased interest in TAVR and miniAVR, only a handful of studies comparing both approaches exist. The goal of this article is to provide an in-depth review of the current literature comparing TAVR and miniAVR for patients with severe AS.

Results

TAVR

One of the major advancements in the management of severe AS came with the introduction of TAVR in 2002. Before this intervention, at least 30% of patients with severe, symptomatic AS did not undergo SAVR due to comorbidities and risk (7). The Placement of Aortic Transcatheter Valves (PARTNER) 1B trial was the first randomized clinical trial comparing TAVR vs. standard therapy in 358 high-risk [mean Society of Thoracic Surgeons Predicted Risk of Mortality (STS PROM) of 11.6%], inoperable patients with severe AS. TAVR was shown to be superior to the standard therapy of medical management and balloon aortic valvuloplasty, with a reduced 1-year all-cause mortality (30.7% vs. 49.7%; P<0.001) (8). The trial revealed lower rates of cardiac symptoms in the TAVR cohort. Of the surviving patients, 74.8% in the TAVR cohort vs. 42% who received standard therapy were asymptomatic or had mild symptoms (New York Heart Association class I or II) at 1 year (P<0.001) (8).

The PARTNER 1A study was a randomized trial comparing TAVR vs. SAVR in 699 high-risk (mean STS PROM of 11.8%), operable patients. The study showed comparable mortality rates at 30 days (3.4% vs. 6.5%; P=0.07) and 1 year (24.2% vs. 26.8%; P=0.44) (9). The rate of all neurologic events (strokes and transient ischemic attacks) was increased in the TAVR cohort at 30 days (5.5% vs. 2.4%; P=0.04) and at 1 year (8.3% vs. 4.3%; P=0.04) (9). The 5-year outcomes were comparable with regard to all-cause mortality (67.8% vs. 62.4%; P=0.76) and all neurologic events (15.9% vs. 14.7%; P=0.35) (10).

The PARTNER 2A trial investigated the use of TAVR in intermediate-risk patients (STS PROM 4–8%) with severe AS. Patients were randomized to either TAVR (with transfemoral and transapical cohorts) or SAVR. No significant difference in all-cause mortality or disabling stroke at 2 years between the TAVR and SAVR groups was found [hazard ratio (HR) =0.89; 95% confidence interval (CI), 0.73 to 1.09; P=0.25] (11). In the transfemoral-access cohort, TAVR resulted in a lower rate of all-cause mortality and disabling strokes (HR =0.79; 95% CI, 0.62 to 1.00; P=0.05) (11). Major vascular complications were more frequent in the TAVR group (7.9% vs. 5.0%; P=0.008) (11). Other complications were less frequent in the TAVR group than in the surgery group, including life-threatening bleeding (10.4% vs. 43.4%; P<0.001), acute kidney injury (1.3% vs. 3.1%; P=0.006), and new-onset atrial fibrillation (9.1% vs. 26.4%; P<0.001) (11).

Thourani et al. conducted a propensity score analysis comparing outcomes at 1 year between intermediate-risk patients who received transfemoral TAVR vs. the intermediate-risk patients in the PARTNER 2A study who received SAVR. They showed superiority of TAVR when using the 3rd generation SAPIEN 3 valve (Edwards Lifesciences, Irvine, CA, USA) over SAVR in terms of reduced mortality (7.4% vs. 13%), stroke (4.6% vs. 8.2%), rehospitalization (11.4% vs. 15.1%), and new-onset atrial fibrillation (5.9% vs. 29.2%) at 1 year (12).

MiniAVR

A second option for minimally invasive AVR is miniAVR. This is typically performed via right anterior thoracotomy or ministernotomy in lieu of a full median sternotomy. This reduces the incision from an average of 24.5 to 7.17 cm with a ministernotomy, or a 5 cm incision with a thoracotomy (13,14). MiniAVR has been shown to: reduce length of intensive care unit (ICU) and hospital stay, reduce ventilation time, decrease the need for blood transfusion, decrease pain, and improve the cosmetic result (15-17). A Cochrane review that included seven randomized controlled trials compared AVR via median sternotomy vs.
MiniAVR to ministernotomy. It illustrated no effect of ministernotomy on mortality [risk ratio (RR) =1.01; 95% CI, 0.36 to 2.82] (18). No increase in aortic cross-clamp (AXC) or cardiopulmonary bypass (CPB) time was found. There was no difference in length of hospital stay.

Phan et al. published a meta-analysis comparing MiniAVR vs. SAVR. The analysis included 50 studies with 12,786 patients. They reported increased AXC (weighted mean difference of 8.09 minutes; P<0.00001) and CPB times (weighted mean difference of 8.16 minutes; P<0.0001) with MiniAVR (19). The MiniAVR cohort was associated with lower rates of perioperative mortality (1.9% vs. 3.3%; P=0.02), perioperative transfusion (36% vs. 52.4%; P=0.001), renal failure (2.5% vs. 4.2%; P=0.04), and length of stay in the ICU (weighted mean difference of −0.6 days) and hospital (−1.34 days; P=0.0007) (19). The two cohorts showed no significant difference in rates of neurologic events, atrial fibrillation, pacemaker implants, and myocardial infarctions (19).

**MiniAVR via thoracotomy vs. ministernotomy**

When discussing MiniAVR, it is important to differentiate between ministernotomy and right minithoracotomy. Miceli et al. reviewed 406 patients who underwent miniAVR with either a right minithoracotomy or ministernotomy. The two groups averaged similar AXC (89.7 vs. 84.3 minutes; P=0.07) and CPB times (124.9 vs. 122.2 minutes; P=0.48) (15). Overall in-hospital mortality was 1.2% with no significant difference between the cohorts (15). The minithoracotomy group experienced a lower incidence of postoperative atrial fibrillation (19.5% vs. 34.2%; P=0.01), shorter ventilation time (median, 7 vs. 8 hours; P=0.003), shorter ICU length of stay (median, 1 day; interquartile range, 1–1; vs. median, 1 day; interquartile range, 1–2; P=0.001), and ward stay (median, 5 vs. 6 days; P=0.0001) (15). No difference in rate was found for postoperative stroke, re-exploration for bleeding, or blood transfusion. The survival rate in the minithoracotomy vs. ministernotomy group at 1 year was 97% vs. 86% and 94% vs. 80% at 5 years, respectively (P=0.1) (15).

Fattouch et al. performed another comparison of miniAVR via minithoracotomy or ministernotomy. In-hospital mortality and death within 30 days of the operation were comparable between both cohorts (1.1% in the minithoracotomy cohort vs. 3.3% in the ministernotomy cohort; P=0.28) (20). AXC (62.6 vs. 62.4 minutes; P=0.11) and CPB times (78.7 vs. 76.8 minutes; P=0.64) were comparable between the minithoracotomy and ministernotomy groups, respectively (20).

**TAVR vs. miniAVR**

Few studies have directly compared TAVR and miniAVR. Miceli et al. retrospectively analyzed patients with severe AS who underwent either TAVR, via transapical or transfemoral approach, or miniAVR via a right thoracotomy with a sutureless valve. After propensity score analysis, 37 matched pairs were compared. The in-hospital mortality rate was 8.1% in the TAVR group and 0% in the miniAVR group (P=0.25) (21). Rates of stroke and transient ischemic attack were 5.4% and 2.7% (P=0.3) in the TAVR group, respective to the approaches noted above, with none occurring in the miniAVR group at a median follow-up period of 13 months (21). Although not statistically significant, the survival rates were higher in the miniAVR cohort compared to TAVR (91.6% vs. 78.6% at 1 year and 91.6% vs. 66.2% at 2 years, respectively (HR =0.7; 95% CI, 0.7 to 49.8; P=0.1)) (21). The TAVR cohort demonstrated higher rates of mild and moderate paravalvular leak (37.8% and 27%, respectively) compared to the miniAVR cohort (2.7% mild and 0% moderate) (P<0.001) (21).

Santarpino et al. reported similar results with a retrospective, propensity score analysis comparing TAVR vs. miniAVR with a sutureless valve in high-risk patients. They report an incidence of aortic regurgitation of 13.5% in the TAVR group vs. 0% in the miniAVR group (P=0.27) and a cumulative survival of 86.5% vs. 97.3% (P=0.015) in the TAVR and miniAVR cohorts respectively, with a mean follow-up of 18.9 months (22).

Terwelp et al. performed a propensity score analysis comparing SAVR, TAVR and miniAVR (23). Analysis of the matched transfemoral TAVR and miniAVR pairs demonstrated no difference in 30-day mortality. Transfemoral TAVR was associated with a higher postoperative stroke rate compared to miniAVR (3.6% vs. 0.4%; P=0.02), but a lower incidence of postoperative atrial fibrillation (4% vs. 19.4%; P<0.01) (23).

**Discussion**

The emergence of TAVR has offered a means to treat inoperable patients with severe AS, with its use quickly expanding to high-risk patients and future applications in sight for intermediate- and low-risk patients. The ability to replace the aortic valve via a small groin incision is a highly...
attractive option to patients, compared to a full sternotomy. However, it has been demonstrated that TAVR is associated with increased perioperative complications, including stroke or transient ischemic attack, incidence of vascular complications, permanent pacemaker implantation, and postoperative moderate and severe para- and transvalvular regurgitation (24). No difference in all-cause mortality has been identified between SAVR and TAVR (9,10,24,25). MiniAVR is a second option for minimally invasive management of AS and has been shown to be equivalent to and possibly better than SAVR in terms of morbidity and mortality, while decreasing blood loss, ICU and hospital length of stays and recovery time (13,19,26-28). The main drawback is the technical difficulty and prolonged AXC and CPB times. However, the utilization of sutureless valve implants has been shown to circumvent both of these pitfalls (21,22,26,29,30). Although miniAVR is more invasive than TAVR, it retains the advantages inherent to SAVR. This includes the insertion of a durable prosthesis, rates of paravalvular leak of <1%, and comparable rates of perioperative myocardial infarction of 0.4% with miniAVR vs. 0.7% with SAVR (P=0.77) (19,31).

A paucity of data exist comparing TAVR and miniAVR. Direct studies are difficult as TAVR patients have typically been high-risk, while miniAVR patients tend to be low-risk, as it is associated with longer AXC and CPB times. Even with propensity score analysis, it is difficult to make comparisons between the two techniques.

Both Miceli and Santarpino demonstrated a reduced survival rate and increased aortic regurgitation in the TAVR cohort (21,22). Terwelpp demonstrated differences in postoperative rates of stroke and atrial fibrillation between TAVR and miniAVR. Therefore, it is important to consider the risk and impact of these complications on the individual patient when choosing between the two (23). The fact that miniAVR has been shown to be equivalent to SAVR in terms of mortality, coupled with decreased blood loss, ventilator time, and ICU and hospital length of stay, may make miniAVR (especially with a sutureless valve) the ideal solution for managing high-risk patients who are not ideal SAVR candidates. However, it is most likely a first-line option for low- and intermediate-risk patients (26).

Just as variable approaches exist for TAVR (transapical vs. transfemoral), miniAVR too can be performed via a number of incision pathways (ministernotomy, minithoracotomy, etc.). Miceli established a higher survival rate at 1 and 5 years and a lower incidence of postoperative atrial fibrillation, shorter ventilation time, decreased ICU and hospital length of stay in the minithoracotomy group as compared to the ministernotomy group (15). These differences demonstrate the need for future studies to separate and distinguish the approaches, in order to more accurately measure and compare miniAVR outcomes.

Considering the current data and literature, we put forth the following opinion for AVR in patients with severe AS; it is clear that TAVR is an indispensable tool for treating severe AS in inoperable patients (8). In high-risk patients, the data appears to support TAVR, and we believe this is an important therapeutic option. The data is less clear for intermediate-risk patients, but from the PARTNER 2A trial and a study by Reardon et al., comparing SAVR vs. TAVR in intermediate-risk patients, it appears that transfemoral TAVR is favorable (11,32). We believe it is important to recognize the potential caveats of these trials. Notably, the average age and STS PROM score for patients in PARTNER 2A were 81 years and 5.8%, respectively (11). Therefore, when evaluating patients for TAVR who are younger, or with a lower STS score, there needs to be recognition that these patients lie outside the demographic of the intermediate-risk trials. The PARTNER 2A study is also limited, in that patients were randomized to TAVR (transfemoral or transapical) or SAVR after being screened to see if the transfemoral approach would be feasible. This represents a selection bias by not randomizing treatment arms and selecting which patients will do better with the transfemoral approach. Another important consideration is that these trials never directly compared TAVR to miniAVR in intermediate-risk patients, and we believe that miniAVR may prove just as efficacious, if not superior.

Without a doubt, TAVR and miniAVR are here to stay. They have both proven to be essential tools that cardiac surgeons need to be comfortable using. With advances in technology and surgical technique, coupled with increased patient demand for minimally invasive procedures, increasing implementation is expected. Thus, it is imperative that more studies be conducted in order to accurately understand and appropriately apply TAVR and miniAVR. Currently, there is no risk-stratified trial directly comparing TAVR and miniAVR and neither technique should be discounted before such a trial is performed.

In conclusion, TAVR and miniAVR are burgeoning options but with little data to compare them. However, we believe there is a compelling role for miniAVR in low- and intermediate-risk patients. In the modern surgical era, even cardiothoracic surgery is beginning to experience the shift towards minimally invasive procedures. There needs to be
randomized, risk-stratified trials comparing TAVR and miniAVR before well-informed guidelines can be created. Either way, cardiac surgeons need to adopt these techniques as the data and outcomes clearly indicate their usefulness and necessity.

Acknowledgements
None.

Footnote
Conflicts of Interest: TC Nguyen is a consultant for Edwards Lifesciences and St. Jude Medical; the other authors have no conflicts of interest to declare.

References


